|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 55511th STREET, NW |
Address2 | Suite #300 |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 288670-12
|
||||||||
|
6. House ID# 371000000
|
TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Keysha Brooks-Coley |
Date | 7/18/2019 2:45:53 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY 2020 federal appropriations for cancer research and prevention funding at the NIH, NCI and CDC; policy issues and funding related to the CDCs and FDAs tobacco work; issues and funding related to non-communicable diseases; funding for development of nuclear isotopes for medical diagnostic technology; and issues related to global health funding for cervical cancer screening & treatment and HPV vaccination.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Disease Control & Prevention (CDC), State - Dept of (DOS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Veterans Affairs - Dept of (VA), U.S. Agency for International Development (USAID), Energy - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Denys |
Symonette |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including:
HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills;
HR 3107, Improving Seniors Timely Access to Care Act of 2019, on prior authorization in the Medicare Advantage Program
CMS-issued regulations pertaining to Medicare Part B reimbursement;
HR 913, The CLINICAL TREATMENT Act, Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trial;
Issues related to potential Administration guidance relating to giving states the option to block grant their Medicaid program;
Issues related to Puerto Ricos Medicaid program, including H.R. 3631, Territories Health Care Improvement Act.
Issues related to utilization management in Medicare Part D plans; issues related to the Medicare Part D caps
Potential legislation for lowering prescription drug costs and lowering out of pocket costs for Medicare beneficiaries; and
CMS proposed regulatory changes on the six protected classes policy within the Medicare Part D prescription drug benefit.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Denys |
Symonette |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
|
Stephanie |
Krenrich |
|
|
|
Phylicia L. |
Woods |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments, including:
Implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation;
Issues relating to FDA regulation of electronic cigarettes and cigars;
S. 655 and H.R.1498, Stopping Appealing Flavors in E-Cigarettes for Kids Act;
S. 1048 and H.R. 2111, Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction Act;
H.R.1854 & S.9, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act;
H.R. 2084, the Stopping Consumption of Tobacco by Teens Act of 2019;
H.R. 2339, Reversing the Youth Tobacco Epidemic Act of 2019;
S. 1258 and H.R. 2411, Tobacco to 21 Act;
Issues related to FDA tobacco control to be considered in House and Senate in the FY20 Agriculture Appropriations legislation and CDC tobacco activities as considered in the Labor, Health and Human Services Appropriations legislation;
H.R. 293, Youth Vaping Prevention Act of 2019;
S. 616, E-Cigarette youth Protection Act;
S. 1253, Preventing Online Sales of E-Cigarettes to Children Act;
S. 1541, Tobacco-Free Youth Act;
S. 1895, Lower Health Care Costs Act regarding tobacco 21 age of sale provisions;
S 1832, Smoke-Free Schools Act;
S. 2726, Banning Smoking on Amtrak Act of 2019; and
Issues related to smoke-free policies for the Veterans Health Administration, H.R. 3700 and S. 2106.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Denys |
Symonette |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues respecting the medical expense deduction.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gregg |
Haifley |
|
|
|
Keysha |
Brooks-Coley |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including:
HR 1010, to provide that the short-term rule has no force or effect;
HR 986 & S 466, Protecting Americans with Pre-Existing Conditions Act;
HR 1425, State Health Care Premium Reduction Act;
HR 1386, Expand Navigators Resources for Outreach, Learning, and Longevity Act of 2019;
HR 1884, Protecting Pre-Existing Conditions & Making Health Care More Affordable Act of 2019;
HR 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019;
HR 1868, the Health Care Affordability Act, to expand subsidies in the ACA individual marketplace
HR 1870, the Family Health Care Affordability Act, to fix the family glitch
S 1935, the Family Coverage Act, to fix the family glitch
Issues related to surprise billing, including HR 3630, the No Surprises Act; S 1895, the Lower Health Care Costs Act; S 1531, the Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019;
Issues relating to curbing health care costs;
H.R.647 & S. 2080, the Palliative Care and Hospice Education and Training Act;
Issues related to Breast Density and Mammography Reporting;
Anti-cancer medication cost-sharing parity respecting H.R. 1409;
A national family caregiving strategy respecting S. 1719 and H.R. 1028;
Issues relating to FDA regulation of laboratory tests, Verifying Accurate Leading-edge IVCT Development Act of 2018 or the VALID Act of 2018;
H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018;
H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for;
H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials;
Additional issues related to reducing disparities in cancer clinical trials;
Issues related to improving quality of life for cancer survivorship;
H.R. 1948 & S. 518, the Lymphedema Treatment Act
H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act;
H.Res. 14 & S.Res. 223, Expressing support for the designation of DIPG Awareness Day
H.R. 1730 and S. 741, the Cancer Drug Parity Act; and
Cannabis research issues, including S. 2032.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), Food & Drug Administration (FDA), White House Office, State - Dept of (DOS), Natl Institutes of Health (NIH), U.S. Agency for International Development (USAID), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Denys |
Symonette |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
|
Stephanie |
Krenrich |
|
|
|
Phylicia L. |
Woods |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |